Results 191 to 200 of about 140,144 (311)

Hepatic Candidiasis Following Drug-Induced Neutropenia in ANCA-Associated Vasculitis: A Diagnostic Challenge. [PDF]

ACG Case Rep J
Park JH, Kumar R, Vikash F, Kumar S, Nankani A, Kajal D, Radulovic M, Patel S.   +7 more
europepmc   +1 more source

Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trial

British Journal of Haematology, EarlyView.
A subgroup analysis of efficacy, safety and QOL in patients who received selinexor in combination with bortezomib and dexamethasone (SVd) with and without selinexor dose reduction and who had lenalidomide‐refractory disease in the phase 3 BOSTON trial showed improvements in efficacy, quality of life (QOL) and safety outcomes with selinexor dose ...
Sosana Delimpasi, Ivan Špička, Jason P. Butler, Don A. Stevens, Mercedes Gironella Mesa, Ceri Bygrave, Giovanni Marino Merlo, Charles la Porte, Meletios A. Dimopoulos   +8 more
wiley   +1 more source

Sacituzumab-induced severe or febrile neutropenia and G-CSF utilization and cost for advanced HER2-negative breast cancer: a single-center retrospective analysis. [PDF]

Breast Cancer Res Treat
Tam G, Waddell D, Freeman JQ, Chen N, Yang H.   +4 more
europepmc   +1 more source

Recurrent Neutropenia [PDF]

Archives of Disease in Childhood, 1951
openaire   +2 more sources

Altered cytoskeletal integrity underlies impaired platelet shape change and defective thrombus formation in ETV6‐related thrombocytopenia

British Journal of Haematology, EarlyView.
Summary ETV6‐related thrombocytopenia (ETV6‐RT) is an inherited platelet disorder caused by germline ETV6 variants. Despite recent progress, the mechanisms underlying platelet dysfunction in ETV6‐RT remain unclear. We investigated 12 patients from six families using functional assays, electron microscopy, quantitative proteomics and cytoskeletal ...
Ivan P. Tesakov, Julia‐Jessica D. Korobkin, Daria V. Fedorova, Sofia V. Galkina, Maria M. Golomysova, Sergei I. Obydennyi, Anastasia A. Ignatova, Ekaterina‐Iva A. Adamanskaya, Eugenia V. Yushkova, Anna V. Pavlova, Pavel A. Zharkov, Igor I. Kireev, Galina A. Novichkova, Viktor G. Zgoda, Mikhail A. Panteleev, Anastasia N. Sveshnikova   +15 more
wiley   +1 more source

Clozapine-Associated Neutropenia among People on Clozapine in Japan: A Nationally Representative Retrospective Cohort Study. [PDF]

Schizophr Bull
Trott M, Northwood K, Hata T, Nishida K, Siskind D, Kanazawa T.   +5 more
europepmc   +1 more source

High frequency of CD95+/CD45RA− regulatory T cells defines an immunosuppressive profile associated with MDS progression

British Journal of Haematology, EarlyView.
Summary Dynamic interactions between mutated haematopoietic cells and immune cells are key drivers of myelodysplastic neoplasms (MDS) initiation and progression. Regulatory T cells (Tregs) are central mediators of immunosuppression in MDS. We thus aimed to characterize Treg subpopulations in the bone marrow (BM) of MDS patients and to explore their ...
Romain Vazquez, Nicolas Deredec, Ismael Boussaid, Pierre Boncoeur, Camille Knosp, Amandine Houvert, Loria Zalmai, Chloe Friedrich, Carole Almire, Charles Dussiau, Lise Willems, Rudy Birsen, Justine Decroocq, Didier Bouscary, Olivier Kosmider, Shahram Kordasti, Michaela Fontenay, Yannick Simoni, Nicolas Chapuis   +18 more
wiley   +1 more source

Drug-induced neutropenia: A comprehensive pharmacovigilance study of the FAERS database. [PDF]

Medicine (Baltimore)
Li J, Wang Y, Gao L, Jia J, Liu J, Jiang Z.   +5 more
europepmc   +1 more source

Drug Neutropenia [PDF]

BMJ, 1970
openaire   +2 more sources

Real‐world treatment patterns and outcomes in accelerated and blast‐phase myeloproliferative neoplasms: Insights from a large multi‐centre cohort analysis in the United Kingdom

British Journal of Haematology, EarlyView.
Summary This UK‐based retrospective analysis describes real‐world treatment patterns and outcomes in 175 patients with accelerated (AP, n = 69) or blast‐phase (BP, n = 106) ‘Philadelphia‐negative’ myeloproliferative neoplasms (MPN‐AP/BP) diagnosed between 2013 and 2025. Median age at transformation was 71 years.
Alexandros Rampotas, Gabriel Naylor‐Layland, Clare Brown, Ahmad Alabdulkarim, Jennifer Ryan, Frances Wadelin, Samah Alimam, Phyo Wint Wint Tun, Jonathan Lambert, Jennifer O'Sullivan, Andrew J. Wilson, Laith Tafesh, Andrew McGregor, Simone Claudiani, Andrew Innes, Emily Booth, James Leveson, Steve Knapper, Mamta Garg, Mani Dubey, Theodora Vatopoulou, Charlotte Brierley, Wai Ka Natalie Leung, Graham Greenfield, Mary Frances McMullin, Alesia Khan, Kate Milne, Duncan Brian, Anna Godfrey, Claire N. Harrison, Bethan Psaila, Patrick Harrington, Amy Kirkwood, Tim C. P. Somervaille, Donal P. McLornan, on behalf of the UK Blood Cancer Research Network MPN Clinical Study Group   +35 more
wiley   +1 more source